Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1).

Ghofrani HA, Gomberg-Maitland M, Zhao L, Grimminger F. Mechanisms and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2024.

Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA. 2022;327(14):1379–91.

Article  CAS  PubMed  Google Scholar 

Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57.

Article  CAS  PubMed  Google Scholar 

Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004;44(7):1488–96.

CAS  PubMed  Google Scholar 

Li A, Zhu Z, He Y, Dong Q, Tang D, Chen Z, et al. DDCI-01, a novel long acting phospdiesterase-5 inhibitor, attenuated monocrotaline-induced pulmonary hypertension in rats. Pulm Circ. 2020;10(4):2045894020939842.

NMPA. Guidelines for estimating the maximum recommended starting dose in initial clinical trials for therapeutics in healthy adult volunteers. China; 2012.

FDA. ADCIRCA (tadalafil) tablets Label. 2009. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022332s011lbl.pdf.

FDA. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers: U.S. Food and Drug Administration (FDA); 2009.

FDA. CIALIS (tadalafil) tablets, for oral use. 2003. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf.

Supuran CT, Mastrolorenzo A, Barbaro G, Scozzafava A. Phosphodiesterase 5 inhibitors–drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr Pharm Des. 2006;12(27):3459–65.

Article  CAS  PubMed  Google Scholar 

Bhat A, Ray B, Mahalakshmi AM, Tuladhar S, Nandakumar DN, Srinivasan M, et al. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders. Pharmacol Res. 2020;160: 105078.

Article  CAS  PubMed  Google Scholar 

Gao ZW, Zhu YT, Yu MM, Zan B, Liu J, Zhang YF, et al. Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model. Acta Pharm Sin. 2015;36(12):1528–36.

Article  CAS  Google Scholar 

Kim BH, Lim HS, Chung JY, Kim JR, Lim KS, Sohn DR, et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008;65(6):848–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hannah-Shmouni F, Faucz FR, Stratakis CA. Alterations of phosphodiesterases in adrenocortical tumors. Front Endocrinol (Lausanne). 2016;7:111.

Article  PubMed  PubMed Central  Google Scholar 

Samidurai A, Xi L, Das A, Kukreja RC. Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders. Annu Rev Pharmacol Toxicol. 2023;20(63):585–615.

Article  Google Scholar 

Korkmaz S, Radovits T, Barnucz E, Neugebauer P, Arif R, Hirschberg K, et al. Dose-dependent effects of a selective phosphodiesterase-5-inhibitor on endothelial dysfunction induced by peroxynitrite in rat aorta. Eur J Pharmacol. 2009;615(1–3):155–62.

Article  CAS  PubMed  Google Scholar 

Qian H, Chen Q, Liang L, Zou Y, Pu H, Xin L, et al. A phase I study to evaluate the safety, tolerability, and pharmacokinetics of TPN171H, a novel phosphodiesterase type 5 inhibitor, in healthy subjects. Drug Des Dev Ther. 2021;15:2947–59.

Article  Google Scholar 

Barnes H, Brown Z, Burns A, Williams T. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev. 2019;1(1):CD012621.

Azzouni F, Abusamra K. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. J Sex Med. 2011;8(10):2894–903.

Article  CAS  PubMed  Google Scholar 

Bellamy TC, Garthwaite J. Pharmacology of the nitric oxide receptor, soluble guanylyl cyclase, in cerebellar cells. Br J Pharmacol. 2002;136(1):95–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhogal S, Khraisha O, Al Madani M, Treece J, Baumrucker SJ, Paul TK. Sildenafil for pulmonary arterial hypertension. Am J Ther. 2019;26(4):e520–6.

Article  Google Scholar 

Food, Drug Administration HHS. International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice. Fed Regist. 2010;75(13):3471–2.

Forgue ST, Phillips DL, Bedding AW, Payne CD, Jewell H, Patterson BE, et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol. 2007;63(1):24–35.

Article  CAS  PubMed  Google Scholar